{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:00:47Z","timestamp":1791388847389,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MedicalScienceResearch Projectof Hebei","award":["20241410"],"award-info":[{"award-number":["20241410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97872-w","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T18:04:32Z","timestamp":1744913072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Liraglutide inhibits the proliferation of rat hepatic stellate cells under high glucose conditions by suppressing the ERK signaling pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Bingge","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"97872_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-981-19-5642-3_17","volume":"1396","author":"V Natesan","year":"2023","unstructured":"Natesan, V. Therapeutics in metabolic diseases. Adv. Exp. Med. Biol. 1396, 255\u2013273 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"97872_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102378","volume":"15","author":"A Kumar","year":"2025","unstructured":"Kumar, A., Arora, A., Sharma, P., Jan, S. & Ara, I. Visceral fat and diabetes: Associations with liver fibrosis in metabolic dysfunction-associated steatotic liver disease. J. Clin. Exp. Hepatol. 15(1), 102378 (2025).","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"3","key":"97872_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s44319-024-00092-y","volume":"25","author":"R Hong","year":"2024","unstructured":"Hong, R. et al. XIAP-mediated degradation of IFT88 disrupts HSC cilia to stimulate HSC activation and liver fibrosis. EMBO Rep. 25(3), 1055\u20131074 (2024).","journal-title":"EMBO Rep."},{"issue":"3","key":"97872_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/HEP.0000000000000569","volume":"79","author":"F Wang","year":"2024","unstructured":"Wang, F. et al. Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A\/HIF-1\u03b1 transcriptional complex. Hepatology 79(3), 606\u2013623 (2024).","journal-title":"Hepatology"},{"issue":"33","key":"97872_CR5","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.3748\/wjg.v29.i33.4975","volume":"29","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Yin, A. H., Sun, J. T., Xu, W. H. & Zhang, C. Q. Angiotensin-converting enzyme 2 improves liver fibrosis in mice by regulating autophagy of hepatic stellate cells. World J. Gastroenterol. 29(33), 4975\u20134990 (2023).","journal-title":"World J. Gastroenterol."},{"key":"97872_CR6","doi-asserted-by":"publisher","first-page":"1092151","DOI":"10.3389\/fphar.2023.1092151","volume":"14","author":"P Chen","year":"2023","unstructured":"Chen, P. et al. Schizandrin C regulates lipid metabolism and inflammation in liver fibrosis by NF-\u03baB and p38\/ERK MAPK signaling pathways. Front. Pharmacol. 14, 1092151 (2023).","journal-title":"Front. Pharmacol."},{"key":"97872_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935180","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan, Y. et al. Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front. Endocrinol. (Lausanne). 13, 935180 (2022).","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"Pt 1","key":"97872_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.freeradbiomed.2022.10.304","volume":"193","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. MTHFR epigenetic derepression protects against diabetes cardiac fibrosis. Free Radic. Biol. Med. 193(Pt 1), 330\u2013341 (2022).","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"97872_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101444","volume":"49","author":"L Weiss","year":"2023","unstructured":"Weiss, L. et al. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis. Diabetes Metab. 49(3), 101444 (2023).","journal-title":"Diabetes Metab."},{"issue":"2","key":"97872_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jceh.2021.07.001","volume":"12","author":"S Chhabra","year":"2022","unstructured":"Chhabra, S. et al. Diabetes mellitus increases the risk of significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. J Clin Exp Hepatol. 12(2), 409\u2013416 (2022).","journal-title":"J Clin Exp Hepatol."},{"issue":"1","key":"97872_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1186\/s12889-024-19177-3","volume":"24","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Temporal relationship between hepatic steatosis and fasting blood glucose elevation: a longitudinal analysis from China and UK. BMC Public Health 24(1), 1865 (2024).","journal-title":"BMC Public Health"},{"key":"97872_CR12","doi-asserted-by":"publisher","first-page":"1078652","DOI":"10.3389\/fendo.2022.1078652","volume":"13","author":"J Hou","year":"2022","unstructured":"Hou, J., Liu, Y., Deng, Z., Sun, J. & Zhao, M. Glycohemoglobin: A new warning strategy for non-alcoholic fatty liver disease: Study from the NHANES 2017\u20132020. Front. Endocrinol. (Lausanne). 13, 1078652 (2022).","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"7","key":"97872_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1316","volume":"13","author":"L Zhong","year":"2023","unstructured":"Zhong, L. et al. Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression. Clin. Transl. Med. 13(7), e1316 (2023).","journal-title":"Clin. Transl. Med."},{"issue":"3","key":"97872_CR14","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s11033-021-07008-2","volume":"49","author":"X Zhou","year":"2022","unstructured":"Zhou, X., Liang, Z., Qin, S., Ruan, X. & Jiang, H. Serum-derived miR-574-5p-containing exosomes contribute to liver fibrosis by activating hepatic stellate cells. Mol. Biol. Rep. 49(3), 1945\u20131954 (2022).","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"97872_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s13105-022-00878-5","volume":"79","author":"M Ruiz de Galarreta","year":"2023","unstructured":"Ruiz de Galarreta, M., Arriazu, E., P\u00e9rez de Obanos, M. P., Ansorena, E. & Iraburu, M. J. Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells. J. Physiol. Biochem. 79(4), 881\u2013890 (2023).","journal-title":"J. Physiol. Biochem."},{"issue":"1","key":"97872_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13071-023-05863-5","volume":"16","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. Recombinant protein EBI3 attenuates Clonorchis sinensis-induced liver fibrosis by inhibiting hepatic stellate cell activation in mice. Parasit. Vectors 16(1), 246 (2023).","journal-title":"Parasit. Vectors"},{"key":"97872_CR17","first-page":"406","volume":"39","author":"M Ten Hove","year":"2024","unstructured":"Ten Hove, M. et al. Engineered SPIONs functionalized with endothelin a receptor antagonist ameliorate liver fibrosis by inhibiting hepatic stellate cell activation. Bioact. Mater. 39, 406\u2013426 (2024).","journal-title":"Bioact. Mater."},{"issue":"1","key":"97872_CR18","doi-asserted-by":"publisher","first-page":"9425","DOI":"10.1038\/s41598-024-59698-w","volume":"14","author":"QQ Liu","year":"2024","unstructured":"Liu, Q. Q., Chen, J., Ma, T., Huang, W. & Lu, C. H. DCDC2 inhibits hepatic stellate cell activation and ameliorates CCl(4)-induced liver fibrosis by suppressing Wnt\/\u03b2-catenin signaling. Sci. Rep. 14(1), 9425 (2024).","journal-title":"Sci. Rep."},{"key":"97872_CR19","first-page":"6731335","volume":"2022","author":"Z Chen","year":"2022","unstructured":"Chen, Z. et al. Mitofusin-2 restrains hepatic stellate cells\u2019 proliferation via PI3K\/Akt signaling pathway and inhibits liver fibrosis in rats. J Healthc. Eng. 2022, 6731335 (2022).","journal-title":"J Healthc. Eng."},{"key":"97872_CR20","first-page":"2501","volume":"42","author":"R Oshins","year":"2024","unstructured":"Oshins, R. et al. Extracellular vesicle-associated neutrophil elastase activates hepatic stellate cells and promotes liver fibrogenesis via ERK1\/2 pathway. bioRxiv. 42, 2501 (2024).","journal-title":"bioRxiv."},{"issue":"12","key":"97872_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166556","volume":"1868","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk\/-Egr-1 signaling and Tgf\u03b21\/Smad pathway in mice. Biochim. Biophys. Acta Mol. Basis Dis. 1868(12), 166556 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"97872_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.116059","volume":"305","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Jiawei Taohe Chengqi Decoction attenuates hepatic fibrosis by preventing activation of HSCs through regulating Src\/ERK\/Smad3 signal pathway. J. Ethnopharmacol. 305, 116059 (2023).","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"97872_CR23","doi-asserted-by":"publisher","first-page":"19087","DOI":"10.4238\/2015.December.29.17","volume":"14","author":"LK Wu","year":"2015","unstructured":"Wu, L. K., Liu, Y. C., Shi, L. L. & Lu, K. D. Glucagon-like peptide-1 receptor agonists inhibit hepatic stellate cell activation by blocking the p38 MAPK signaling pathway. Genet. Mol. Res. 14(4), 19087\u201319093 (2015).","journal-title":"Genet. Mol. Res."},{"key":"97872_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113236","volume":"152","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. Biomed. Pharmacother. 152, 113236 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"97872_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106426","volume":"184","author":"P Yadav","year":"2022","unstructured":"Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R. & Navik, U. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. Pharmacol. Res. 184, 106426 (2022).","journal-title":"Pharmacol. Res."},{"issue":"3","key":"97872_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17474124.2023.2172397","volume":"17","author":"Y Gu","year":"2023","unstructured":"Gu, Y. et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: Systematic review and pilot network meta-analysis of randomized controlled trials. Expert. Rev. Gastroenterol. Hepatol. 17(3), 273\u2013282 (2023).","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"97872_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40842-016-0027-7","volume":"2","author":"P Portillo-Sanchez","year":"2016","unstructured":"Portillo-Sanchez, P. & Cusi, K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin. Diabetes Endocrinol. 2, 9 (2016).","journal-title":"Clin. Diabetes Endocrinol."},{"issue":"3","key":"97872_CR28","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1080\/21655979.2022.2036902","volume":"13","author":"J Ji","year":"2022","unstructured":"Ji, J., Feng, M., Huang, Y. & Niu, X. Liraglutide inhibits receptor for advanced glycation end products (RAGE)\/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered 13(3), 5091\u20135102 (2022).","journal-title":"Bioengineered"},{"issue":"8","key":"97872_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/liv.14888","volume":"41","author":"N Perakakis","year":"2021","unstructured":"Perakakis, N. et al. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int. 41(8), 1853\u20131866 (2021).","journal-title":"Liver Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97872-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T18:04:33Z","timestamp":1744913073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97872-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97872"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97872-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13360"}}